Obstetrics and gynecology
-
Obstetrics and gynecology · Feb 2006
Case ReportsBaking soda pica: a case of hypokalemic metabolic alkalosis and rhabdomyolysis in pregnancy.
We report a case of baking soda pica in a woman at 31 weeks of pregnancy causing severe hypokalemic metabolic alkalosis and rhabdomyolysis. ⋯ Pica is a common but often overlooked practice that can potentially lead to life-threatening disorders. A thorough evaluation of a patient's dietary intake is extremely important, especially in the setting of atypical presentations of disease in pregnancy.
-
Obstetrics and gynecology · Feb 2006
Review Case ReportsExtracorporeal membrane oxygenation therapy for circulatory arrest due to postpartum hemorrhage.
Cardiac arrest after postpartum hemorrhage may not respond to advanced life support. Various resuscitation methods have been proposed, including sternotomy and direct cardiac massage. Extracorporeal membrane oxygenation (ECMO) might be an alternative. ⋯ Aggressive mechanical circulatory support, such as ECMO, should be considered in a case of potentially reversible cardiocirculatory failure in a young obstetric patient.
-
Obstetrics and gynecology · Feb 2006
Universal perinatal depression screening in an Academic Medical Center.
To develop a department-based program to identify and treat women at risk for perinatal depression. ⋯ III.
-
Obstetrics and gynecology · Feb 2006
Single-dose fluconazole for vulvovaginal candidiasis: impact on prothrombin time in women taking warfarin.
To estimate the effect of a single oral 150-mg dose of fluconazole on the prothrombin time of women on long-term warfarin therapy. ⋯ II-2.
-
Obstetrics and gynecology · Jan 2006
Randomized Controlled Trial Comparative StudyEfficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.
Human papillomavirus (HPV) virus-like particle (VLP) vaccines have demonstrated effectiveness in preventing persistent HPV infections. Whether protection lasts longer than 18 months and, thus, impacts rates of cervical intraepithelial neoplasia (CIN) 2-3 has not yet been established. We present results from an HPV16 L1 VLP vaccine trial through 48 months. ⋯ I.